Oncolytic virotherapy for multiple myeloma

Expert Opinion on Biological Therapy

Volumn 8, Issue 4, 2008, Pages 463-473

  Stief, Amaalia E ^a   McCart, J Andrea ^a,b,c,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Multiple myeloma; Oncolytic virus; Tumour targeting; Virotherapy

Indexed keywords

BORTEZOMIB; DEATH RECEPTOR 4 ANTIBODY; DEXAMETHASONE; IODINE 124; IODINE 125; IODINE 131; ONCOLYTIC ADENOVIRUS; ONCOLYTIC COXSACKIEVIRUS A21; ONCOLYTIC MEASLES VIRUS; ONCOLYTIC MYXOMA VIRUS; ONCOLYTIC REOVIRUS; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; ONYX 015; RADIOPHARMACEUTICAL AGENT; RAPAMYCIN; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; REVIEW; VIRUS CARRIER; VIRUS INFECTION; VIRUS REPLICATION; ANIMAL; ANTIBODY PRODUCTION; AUTOTRANSPLANTATION; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; GENETICS; IMMUNOLOGY; METHODOLOGY; MULTIMODALITY CANCER THERAPY; VIROLOGY;

COXSACKIEVIRUS; MEASLES VIRUS; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, VIRAL; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; HUMANS; MULTIPLE MYELOMA; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TRANSPLANTATION, AUTOLOGOUS; VIRUS REPLICATION;

EID: 42149158421     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.4.463     Document Type: Review

References (77)

1. Albano A. Adaptation of rat myeloma cells to continuous culture and their susceptibility to enteroviruses, adenoviruses, and measles virus. Boll Ist Sieroter Milan 1962;41:599-607
2. Kawa A, Arakawa S. The effect of attenuated vaccinia virus AS strain on multiple myeloma; A case report. Jpn J Exp Med 1987;57(1):79-81
3. Meeker TC, Lay LT, Wroblewski JM, et al. Adenoviral vectors efficiently target cell lines derived from lymphocytic malignancies, including anaplastic large cell lymphoma and Hodgkin's disease. Clin Cancer Res 1997;3:357-64
4. Ito T, Wang D-Q, Maru M, et al. Antitumor efficacy of vaccinia virus-modified tumor cell vaccine. Cancer Res 1990;50:6915-8
5. Phase I Trial: Vaccine Therapy with or without Cyclophosphamide in Treating Patients with Recurrent or Refractory Multiple Myeloma. Available from: www.clinicaltrials.gov/cr/show/ NCT00450814?order=1 [last accessed January 18, 2008] •• The first clinical trial using an oncolytic virus (measles) to treat MM.
6. Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther 2002;9:961-6
7. Wen XY, Mandelbaum S, Li ZH, et al. Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7.1) for the immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther 2001;8(5):361-70
8. Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3(6):639-45
9. Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. Human Gene Ther 2003;14:933-46
10. Heise C, Herminston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6(10):1134-9
11. Cascallo M, Capella G, Mazo A, Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. Cancer Res 2003;63:5544-50
12. McCart JA, Wang ZH, Xu H, et al. Development of a melanoma-specific adenovirus. Mol Ther 2002;6(4):471-80
13. Rodriguez R, Schuur ER, Lim HY, et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57:2559-63
14. Turturro F. Recombinant adenovirus-mediated cytotoxic genetherapy of lymphoproliferarive disorders: is CAR important for the vector to ride. Gene Ther 2003;10(2):100-4
15. Dmitriev I, Kashentseva E, Rogers BE, et al. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol 2000;74(15):6875-84
16. Li HJ, Everts M, Pereboeva L, et al. Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic bispecific adapter. Cancer Res 2007;67(11):5354-61
17. Peng K-W, Donovan KA, Schneider U, et al. Oncolytic measles virus displaying a single chain antibody against CD38, a myeloma cell marker. Blood 2003;101(7):2557-62
18. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003;9(11):1408-12
19. Strair R, Sheay W, Goodell L, et al. Adenovirus infection of primary malignant lymphoid cells. Leuk Lymphoma 2002;43(1):37-49
20. Moss B. Poxviridae: the viruses and their replication. In: Fields Virology. Knipe DM, Howley PM, editors. Philadelphia, Lippincott, Williams & Wilkins; 2001. p. 2849-84
21. Shen Y, Nemunaitis J. Fighting cancer with vaccinia virus: teaching new tricks to an old dog. Mol Ther 2005;11(2):180-95
22. Fenner F, Wittek R, Dumbell KR. The Orthopoxviruses. New York, Academic Press, Inc.; 1989. p. 143-70
23. Moss B. Vaccinia Virus. A Tool for Research and Vaccine Development. Science 1991;252:1662-7
24. Kim JH, Oh JY, Park BH, et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 2006;14(3):361-70
25. Zeh HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther 2002;(9):1001-12
26. McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751-7 • The first description of an attenuated, WR strain, vaccinia virus.
27. Guo ZS, Naik A, O'Malley ME, et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005;65(21):9991-8
28. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996;93:11341-8
29. Moss B, Earl PL. Expression of proteins in mammalian cells using vaccinia viral vectors. In: Ausubel FM, Brent R, Kingston RE, et al., editors. New York, NY: John Wiley. Curr Prot Mol Biol 1998;43:16.15.1-16.19.11.
30. Griffin DE. Measles Virus. In: Fields Virology. Fields BN, Knipe DM, Howley PM, editors. Philadelphia, Lippincott, Williams, Wilkins; 2001. p. 1401-42
31. Nakamura T, Russell SJ. Oncolytic measles viruses for cancer therapy. Expert Opin Biol Ther 2004;4(10):1685-92
32. Anderson BD, Nakamura T, Russell SJ, Peng K-W. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 2004;64:4919-26 •• An important paper that describes MV-Edm selectivity for cancer cells.
33. Ong HT, Timm MM, Greipp PR, et al. Oncolytic measels virus targets high CD46 expression on muliple myeloma cells. Exp Hematol 2006;34:713-20 • The first description of upregulated CD46 on myeloma cells.
34. Radecke F, Spielhofer P Schneider H, et al. Rescue of measles viruses from cloned DNA. EMBO J 1995;14(23):5773-84
35. Nakamura T, Peng K-W, Harvey M, et al. Rescue and propagation of fully retargeted oncolytic measles virus. Nat Biotechnol 2005;23(2):209-14
36. Dingli D, Peng K-W, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measels virus expressing the thyroidal sodium iodide symporter. Blood 2004;103(5):1641-6 • The results presented showed the importance of combination therapy in overcoming resistant tumours in mice.
37. Rose JK, Whitt MA. Rhabdoviridae: The Viruses and their Replication. In: Fields Virology. Fields BN, Knipe DM, Howley PM, editors. Philadelphia, Lippincott Williams & Wilkins; 2001. p. 1221-43
38. Stojdl DF, Abraham N, Knowles S, et al. The murine double-stranded RNA-dependent protein kinase PKR is required for resistence to vesicular stomatitis virus. J Virol 2000;74(20):9580-5
39. Stojdl DF, Lichty BD, tenOever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003;4:263-75 •• An important paper evaluating the oncolytic properties of VSV mutants.
40. Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or Myc function and involves the induction of apoptosis. J Virol 2001;75(7):3474-9
41. Noser JA, Mael AA, Sakuma R, et al. The ras/raf1/mek/erk signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol Ther 2007;15(8):1531-6
42. Lichty BD, Power AT, Stojdl DF, Bell JC. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 2004;10(5):210-6
43. Goel A, Carlson SK, Classic KL, er al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta 51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodidie symporter gene. Blood 2007;110(7):2342-50 •• An important paper describing the use of combined radiovirotherapy to treat MM in immunocompetent murine models.
44. Nibert ML, Schiff LA. Reoviruses and their Replication. In: Fields Virology. Fields BN, Knipe DM, Howley PM, editors. Philadelphia, Lippincott Williams & Wilkins; 2001. p. 1679-720
45. Coffey MC, Strong JE, Forsyth PA, Lee PWK. Reovirus therapy of tumors with activated ras pathway. Science 1998;282:1332-4
46. Norman KL, Hirasawa K, Yang A-D, et al. Reovirus oncolysis: the ras/ralGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004;101(30):11099-104
47. Alain T, Hirasawa K, Pon KJ, et al. Reovirus therapy of lymphoid malignancies. Blood 2002;100(12):4146-53 • The first description of reovirus for treating lymphoid malignancies in mice.
48. Thirukkumaran CM, Luider JM, Stewart DA, et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood 2003;102(1):377-87
49. Shafren DR, Au GG, Nguyen T, et al. Systemic therapy of malignant human melanoma tumours by a common cold-producing enterovirus, coxsackievirus A21. Clin Cancer Res 2004;10:53-60
50. Au GG, Lincz LF, Enno A, Shafren DR. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol 2007;137:133-41 • The first description of coxsackievirus A21 therapy for myeloma in preclinical models.
51. Racaniello VR. Picornaviridae: The Viruses and their Replication. In: Fields Virology. Knipe DM, Howley PM, editors. Philadelphia, Lippincott, Williams & Wilkins; 2001. p. 685-722
52. Shafren DR. Viral cell entry induced by cross-linked decay-accelerating factor. J Virol 1998;72(11):9407-12
53. Shafren DR, Dorahy DJ, Ingham RA, et al. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol 1997;71(6):4736-43
54. Alexander DD, Mink PJ, Adami H-O, et al. Multiple myeloma: a review of the epidemilogic literature. Int J Cancer 2007;120:40-61
55. Multiple myeloma/other plasma cell neoplasms. Available from: http://www. cancer.gov/cancertopics/types/myeloma [last accessed January 18, 2008]
56. Canadian Cancer Statistics 2007. Toronto, Canada, Canadian Cancer Society/National Cancer Institute of Canada. 2007. Available from: 129.33.170.32/vgn/images/portal/cit_86751114/36/15/1816216925cw_2007stats_en. pdf [last accessed January 18, 2008]
57. McElwain TJ, Selby PJ, Gore ME, et al. High-dose chemotherapy and autologous bone marrow transplantation for myeloma. Eur J Haematol Suppl 1989;51:152-6
58. Hideshima T, Richardson P, Chauhan D, et al. The proteosome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistence in human multiple myeloma cells. Cancer Res 2001;61:3071-6
59. Richardson PG, Mitsiades CS, Hideshima T, Anderson KC. Novel biological therapies for the treatment of multiple myeloma. Best Practice & Res Clin Hematol 2005;18(4):619-34
60. Trudel S, Li ZH, Wei E, et al. CHIR-258, a novel multitargeted tyrosine kinase inhibiror for the potential treatment of t(4;14) multiple myeloma. Blood 2005;105(7):2941-8
61. Trudel S, Li ZH, Rauw J, et al. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007;109:5430-8
62. Fonseca R, Stewart AK. Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther 2007;6(3):802-10
63. Dingli D, Peng K-W, Harvey ME, et al. Interaction of measles virus vectors wirh Auger electron emitting radioisotopes. Biochem Biophys Res Comm 2005;337:22-9 • This paper documents the decreased immune response to MV in myeloma patients.
64. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase 1 trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B cell malignancies. J Clin Oncol 2005;23:6719-29
65. Peng KW, Ahmann GJ, Pham L, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001;98(7):2002-7 • The first description of an attenuated measles virus to treat murine models of myeloma.
66. Lichty BD, Stojdl DF, Taylor RA, et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematological malignancy. Human Gene Ther 2004;15:821-31 • The first description of attenuated VSV for treating myeloma in preclinical models.
67. Hallak LK, Merchan JR, Storgard CM, et al. Targeted measels virus vector displaying echistatin infects endothelial cells via αvβ3 and leads to tumor regression. Cancer Res 2005;65(12):5292-300
68. Ong HT, Hasegawa K, Dietz AB, et al. Evaluation of T cells as carriers for systemic measels virotherapy in the presence of antiviral antibodies. Gene Ther 2007;14:324-33
69. Iankov I, Blechacz B, Liu C, et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measels viruses in cancer virotherapy. Mol Ther 2007;15(1):114-22 • The authors successfully used monocytes to systemically deliver MV to murine tumours and avoid neutralization by antibodies.
70. Grandvaux N, tenOever BR, Servant MJ, Hiscott J. The interferon viral response: from viral invasion to evasion. Curr Opin Infect Dis 2002;15:259-67
71. Haralambieva I, Iankov I, Hasegawa K, et al. Engineering oncolytic measels virus to circumvent the intracellular innate immune response. Mol Ther 2007;15(3):588-97
72. 111In-pentetreotide. Mol Ther 2004;10(3):553-61
73. Dingli D, Kemp BJ, O'Connor MK, et al. Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously trabsfected tumor. Mol Imaging Biol 2006;8:16-23
74. Chauhan D, Pandey P, Ogata A, et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 1997;15:837-43
75. Strömberg T, Dimberg A, Hammarberg A, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004;103:3138-47
76. Stanford MM, Barrett JW, Nazarian SH, et al. Oncolytic virotherapy synergy with signaling inhibitors: Rapamycin increases myxoma virus tropism for human cells. J Virol 2007;81(3):1251-60 • The first paper indicating that rapamycin can be used to improve oncolytic virus activity.
77. Johnson TR, Stone K, Nikrad M, et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003;22(32):4953-63